Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.

Moderna ETFs to Gain on Positive 'Real-World' Study Data

More than two-thirds of those jabs have already been administered.

Moderna Has Shipped 100 Million Coronavirus Vaccine Doses to the U.S.

Pfizer

Pfizer and Moderna vaccines 80% effective at preventing COVID-19 after one shot, CDC says

Covid-19 vaccine stocks tumbled Monday despite a real-world study showing Moderna's and Pfizer's two-dose coronavirus vaccines are 80% effective after the first dose. The post CDC Head Expresses Sense Of 'Impending Doom' Despite New Vaccine Study appeared first on Investor's Business Daily.

CDC Head Expresses Sense Of 'Impending Doom' Despite New Vaccine Study

The study shows the vaccines prevent all coronavirus infections, not just symptomatic ones.

CDC: Pfizer And Moderna Vaccines Could Significantly Cut Down On Coronavirus Transmission

The two-dose COVID-19 vaccines from Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) lower the risk for infection by up to 90%, according to data released by the U.S. Centers for Disease Control and Prevention. The study was released in Morbidity and Mortality Weekly Report, an online journal published by the Centers for Disease Control and Prevention.

CDC New Study Shows Pfizer, Moderna COVID-19 Shots 90% Effective Against Infection In Real-World Setting

A single dose of Pfizer or Moderna's Covid-19 vaccines was 80% effective in preventing infections, according to a new CDC study.

One dose of Pfizer or Moderna vaccines was 80% effective in preventing Covid in CDC study of health workers

Moderna Inc. said Monday it has shipped the 100 millionth dose of its COVID-19 vaccine to the U.S. government and expects to meet its commitment dates for all current orders, including delivering a second 100 million doses by the end of May and a third 100 million by end-July. Since the vaccine was granted emergency use authorization by the U.S. Food and Drug Administration in December, Moderna shipped more than 16 million doses in January, 26 million in February and 44 million to date in March.

Moderna says on track to deliver second 100 million doses to US. government by end May

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces shipment of 100 millionth dose of its COVID-19 Vaccine to the U.S. Government.

Moderna Announces Shipment of 100 Millionth Dose of its COVID-19 Vaccine to the U.S. Government

Novavax

The Serum Institute of India says the jointly developed Covovax has an overall efficacy of 89%.

Moderna vaccine to arrive in U.K. imminently as India starts testing Novavax inoculation

Moderna Vaccine Set to Arrive in U.K. as India Starts Testing Novavax Inoculation

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock?

Why Is Moderna (MRNA) Down 10.2% Since Last Earnings Report?

With production ramping to 1.4 billion doses and next-gen vaccine in trials, don't underestimate Covid-19 vaccine upside for MRNA stock. The post Covid-19 Vaccine Orders Are Piling Up, Moderna Stock Has Room to Grow appeared first on InvestorPlace.

Covid-19 Vaccine Orders Are Piling Up, Moderna Stock Has Room to Grow

Moderna stock has declined by about -12% over the last week (five trading days), compared to the S&P 500 which is down by about -1.2% over the same period. Although there hasn't been too much news relating to the company, Moderna stock has likely been hurt by the broader sell-off in high-growth.

Will Moderna Stock Rally After 12% Decline Last Week?

Moderna Inc's (NASDAQ: MRNA) CEO Stéphane Bancel in an interview with Forbes, said that the company would continue with its work on new vaccines for a range of indications other than COVID-19, including infectious disease, cancer treatments, and genetic disorders like cystic fibrosis. Vaccine for COVID-19 variants: Moderna has already shipped a new batch of COVID-19 vaccines to the National Institutes of Health for testing targeting the B.1.351 variant first discovered in South Africa.

Moderna's CEO Outlines Non-COVID Pipeline View

The biotech is working on a next-generation vaccine that could provide significant competitive advantages.

Look Out: Moderna Could Have an Even Better COVID Vaccine on the Way

One of the world's first mRNA vaccines made Bancel a billionaire—and now the biotech CEO discusses his plans to use the mRNA breakthrough for cancer, genetic disorders, and even a better flu vaccine.

What's Next For Moderna Post-Covid-19: CEO Stephane Bancel Details mRNA Pipeline

AstraZeneca

BioNTech SE

Johnson & Johnson

Viatris

This question has multiple right answers.

Which COVID Vaccine Stock Is the Best Pick?

Alpha Pro Tech

DocuSign

iBio

Peloton

Sorrento Therapeutics Inc

Because of the pandemic, many so-called Covid stocks enjoyed outsized gains but investors might want to consider trimming their exposure. The post Take Your Profits!

Take Your Profits! 7 Covid Winners to Sell Now

Moderna Inc. said Monday that it reached an agreement to supply the Philippines with an additional seven million doses of its COVID-19 vaccine. That brings the total number of doses the Philippines has secured from Moderna to 20 million, including the previously announced supply agreement of 13 million doses, in which deliveries would begin in mid-2021.

Moderna to supply the Philippines with an additional 7 million doses of COVID-19 vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new supply agreement with the Philippines for 7 million additional doses of COVID-19 Vaccine Moderna.

Moderna Announces New Supply Agreement with the Philippines for 7 Million Additional Doses of COVID-19 Vaccine Moderna

Many people have rushed to invest in vaccine markers. Here's why this Fool didn't.

Why I Didn't Jump on the Coronavirus Vaccine Stock Bandwagon

Some stocks could be big winners and losers depending on what the answer to this question is.

The Multibillion-Dollar Question: How Long Do COVID Vaccines Last?

New trading platform functionality has made expensive stocks accessible.

Even Moderna Can Be a Penny Stock with Fractional Shares

The vaccine maker's shares have fallen sharply in the past month as investors appear to be moving away from COVID-19 stocks.

News for Moderna Stock (MRNA)